{"id":1011960,"date":"2026-10-20T16:16:28","date_gmt":"2026-10-20T20:16:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"},"modified":"2026-10-20T16:16:28","modified_gmt":"2026-10-20T20:16:28","slug":"viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","title":{"rendered":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026<\/b><\/p>\n<p>WALTHAM, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nViridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026.<\/p>\n<p>\nManagement will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A webcast of the conference call can be accessed through the \u201cEvents &amp; Presentations\u201d page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available in the Investors section of the Company\u2019s website.<\/p>\n<p><b><span class=\"bwuline\">About Viridian Therapeutics<\/span><\/b><\/p>\n<p>\nViridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.<\/p>\n<p>\nWith an immediate focus in thyroid eye disease (TED), we developed Lumvoa<sup>TM<\/sup>, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.<\/p>\n<p>\nViridian is based in Waltham, Massachusetts. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.viridiantherapeutics.com&amp;esheet=54625742&amp;newsitemid=20261020707364&amp;lan=en-US&amp;anchor=www.viridiantherapeutics.com&amp;index=1&amp;md5=d7bfc4b5f5f5a980600b354df6aacba0\">www.viridiantherapeutics.com<\/a>. Follow Viridian on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fviridiantx&amp;esheet=54625742&amp;newsitemid=20261020707364&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=9f7087798e09de1e403e47146e7dd735\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FViridianThera&amp;esheet=54625742&amp;newsitemid=20261020707364&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=9d96e508a5f1113f20563bc94a7e06ac\">X<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261020707364\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261020707364\/en\/<\/a><\/span><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/>Greg Rossino<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:grossino@viridiantherapeutics.com\">grossino@viridiantherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261020707364\/en\/2003056\/3\/Viridian_Logo_-_Jan.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A webcast of the conference call can be accessed through the \u201cEvents &amp; Presentations\u201d page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011960","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A webcast of the conference call can be accessed through the \u201cEvents &amp; Presentations\u201d page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available &hellip; Continue reading &quot;Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-20T20:16:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026\",\"datePublished\":\"2026-10-20T20:16:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\"},\"wordCount\":304,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\",\"name\":\"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-20T20:16:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk","og_description":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A webcast of the conference call can be accessed through the \u201cEvents &amp; Presentations\u201d page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available &hellip; Continue reading \"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-20T20:16:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026","datePublished":"2026-10-20T20:16:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"},"wordCount":304,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","name":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-20T20:16:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261020707364r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011960"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}